<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of hypertension in patients with diabetes mellitus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of hypertension in patients with diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of hypertension in patients with diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William B White, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3155323002"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diabetes mellitus is a common disorder, affecting nearly half a billion people worldwide and 8 to 9 percent of the population in the United States.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1771.html" rel="external">"Type 2 diabetes mellitus: Prevalence and risk factors", section on 'Prevalence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents", section on 'Epidemiology'</a>.)</p><p></p><p>Hypertension occurs frequently in patients with diabetes and, together, diabetes and hypertension substantially increase the risk of cardiovascular and kidney disease. Effective treatment of hypertension in such patients reduces cardiovascular risk. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120405">(Related Pathway(s):  <a class="utd-content-120405" href="/pathway/120405?topicRef=3829&amp;source=see_link">Hypertension: Initial management</a>.)</span></p><p>The pathogenesis, epidemiology, and choice of antihypertensive therapy in patients with diabetes mellitus are presented in this topic. The diagnosis of hypertension and goal blood pressure in patients with diabetes are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3879.html" rel="external">"Blood pressure measurement in the diagnosis and management of hypertension in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'</a>.)</p><p></p><p class="headingAnchor" id="H700287065"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>In addition to the development of kidney disease, at least two other factors have been proposed to contribute to hypertension in diabetes: extracellular fluid volume expansion and increased arterial stiffness [<a href="#rid1">1</a>].</p><p>Sodium retention and volume expansion may be induced both by insulin and the hyperglycemia-induced increase in the filtered glucose load [<a href="#rid2">2,3</a>]. The excess filtered glucose is reabsorbed in the proximal tubule via a sodium-glucose cotransporter, resulting in a parallel rise in sodium reabsorption [<a href="#rid3">3</a>]. Thus, salt loading tends to raise the blood pressure, an effect that can be reversed by salt restriction.</p><p>Patients with diabetes have increased vascular stiffness [<a href="#rid1">1</a>], which is thought to be a consequence of increased protein glycation and, at a later stage, atheromatous disease. The reduction in arterial distensibility, which is seen with both impaired glucose tolerance and overt diabetes, can contribute to the rise in systolic pressure disproportionately to diastolic pressure and is associated with increased blood pressure variability and mortality risk [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H4272330371"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hypertension is a common problem in patients with both type 1 and type 2 diabetes, but the time course in relation to the duration of diabetes is different [<a href="#rid2">2,6-9</a>].</p><p>Among those with type 1 diabetes, the incidence of hypertension rises from 5 percent at 10 years, to 33 percent at 20 years, and to 70 percent at 40 years [<a href="#rid2">2</a>]. There is a close relation between the prevalence of hypertension and increasing albuminuria. The blood pressure typically begins to rise within the normal range at or within a few years after the onset of moderately increased albuminuria (the new term for what was previously called "microalbuminuria" and what is also sometimes called "high albuminuria") [<a href="#rid7">7</a>]. Blood pressure then increases progressively as the kidney disease progresses. (See  <a class="medical medical_review" href="/d/html/3110.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 1 diabetes mellitus", section on 'Risk factors'</a>.)</p><p>These features were illustrated in a study of 981 patients who had type 1 diabetes for five or more years [<a href="#rid8">8</a>]. Hypertension was present in 19 percent of patients with normoalbuminuria, 30 percent with moderately increased albuminuria, and 65 percent with severely increased albuminuria (the new term for what was previously called "macroalbuminuria" and what is sometimes called "very high albuminuria") [<a href="#rid7">7</a>]. The incidence of hypertension eventually reaches 75 to 85 percent in patients with progressive diabetic nephropathy [<a href="#rid10">10</a>]. The risk of hypertension is highest in Black individuals, who are also at much greater risk for kidney failure due to diabetic kidney disease. (See  <a class="medical medical_review" href="/d/html/3103.html" rel="external">"Diabetic kidney disease: Pathogenesis and epidemiology"</a>.)</p><p>The findings are different in patients with type 2 diabetes [<a href="#rid11">11-13</a>]. In a series of over 3500 newly diagnosed patients, 39 percent were already hypertensive [<a href="#rid11">11</a>]. In approximately one-half of these patients, the elevation in blood pressure occurred before the onset of moderately increased albuminuria. Hypertension was strongly associated with obesity, and not surprisingly, the hypertensive patients were at increased risk for cardiovascular morbidity and mortality. Among patients with diabetes in general (regardless of vintage) in the United States, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fdiabetes%2Fdata%2Fstatistics-report%2Fappendix.html&amp;token=5lAfyzQxoRDHD86hVMfck%2BpPyAYXPzwcdS4FMC926JYvVpjd9VQk3BsV%2Fl63%2F%2FuTdTdH9%2B0Ek3aKZy8rcFVUT6LL%2Ffq7PAZYoYoo2npPT%2FI%3D&amp;TOPIC_ID=3829" target="_blank">prevalence of hypertension</a> is nearly 70 percent. (See  <a class="medical medical_review" href="/d/html/3089.html" rel="external">"Moderately increased albuminuria (microalbuminuria) in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H389779526"><span class="h1">GOAL BLOOD PRESSURE</span><span class="headingEndMark"> — </span>UpToDate recommendations on goal blood pressure in hypertensive patients with diabetes mellitus are presented in detail elsewhere. In general, patients with diabetes are at higher cardiovascular risk compared with the general population, and therefore we suggest more intensive, rather than less intensive, blood pressure control. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'</a>.)</p><p>Goal blood pressure also depends upon the method by which it is measured  (<a class="graphic graphic_table graphicRef117101" href="/d/graphic/117101.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Importance of how blood pressure is measured'</a>.)</p><p>Our recommendations are broadly consistent with the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines [<a href="#rid14">14</a>], as well as the American Diabetes Association (ADA) guidelines that suggest a goal blood pressure of less than 130/80 mmHg in patients with diabetes mellitus who have greater than a 10 percent 10-year cardiovascular risk [<a href="#rid15">15</a>].</p><p>Support for these recommendations comes from randomized trials, meta-analyses, and large observational studies [<a href="#rid16">16-19</a>]. A detailed presentation of the rationale for our approach, including a discussion of the Action to Control Cardiovascular Risk in Diabetes blood pressure trial (ACCORD BP) [<a href="#rid20">20</a>], is found in a separate topic. (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'</a>.)</p><p class="headingAnchor" id="H172154995"><span class="h1">APPROACH TO LOWERING BLOOD PRESSURE</span><span class="headingEndMark"> — </span>Since hypertension magnifies cardiovascular risk among those with diabetes, all patients with diabetes and persistently elevated blood pressure should be started on antihypertensive drug therapy [<a href="#rid21">21-25</a>]. Drug therapy in patients with diabetes and hypertension is unequivocally protective [<a href="#rid16">16,26-32</a>]. (See <a class="local">'Choice of antihypertensive drug therapy'</a> below.)</p><p>In addition, all patients with diabetes and elevated blood pressure should be counseled on lifestyle modification to reduce blood pressure. Successful implementation of nonpharmacologic therapy may permit later reduction in the dose or number of antihypertensive agents. (See <a class="local">'Nonpharmacologic therapy (lifestyle modification)'</a> below and  <a class="medical medical_review" href="/d/html/3864.html" rel="external">"Tapering and discontinuing antihypertensive medications"</a>.)</p><p class="headingAnchor" id="H3151778055"><span class="h2">Nonpharmacologic therapy (lifestyle modification)</span><span class="headingEndMark"> — </span>Nonpharmacologic interventions to prevent and treat hypertension include lifestyle modifications such as  (<a class="graphic graphic_table graphicRef116041" href="/d/graphic/116041.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Salt restriction (see  <a class="medical medical_review" href="/d/html/3877.html" rel="external">"Salt intake and hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Weight reduction (see  <a class="medical medical_review" href="/d/html/3875.html" rel="external">"Overweight, obesity, and weight reduction in hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased consumption of fresh fruits, vegetables, and low-fat dairy products (see  <a class="medical medical_review" href="/d/html/3878.html" rel="external">"Diet in the treatment and prevention of hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased exercise (see  <a class="medical medical_review" href="/d/html/3828.html" rel="external">"Exercise in the treatment and prevention of hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of smoking and excess alcohol ingestion (see  <a class="medical medical_review" href="/d/html/3866.html" rel="external">"Smoking and hypertension"</a> and  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Nonpharmacologic therapy'</a>)</p><p></p><p>We agree with the American Diabetes Association (ADA) 2020 guidelines, which advise that, among patients with a systolic blood pressure ≥120 mmHg or a diastolic pressure ≥80 mmHg, such nonpharmacologic methods should be used to reduce blood pressure [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H4124640684"><span class="h2">When to initiate antihypertensive drug therapy</span><span class="headingEndMark"> — </span>The decision to initiate drug therapy should be individualized and involve shared decision-making between patient and provider. In general, however, we suggest that antihypertensive drug therapy be initiated in the following hypertensive patients (our suggestions broadly agree with those recommendations made by the 2017 American College of Cardiology/American Heart Association [ACC/AHA] guidelines and by the 2020 ADA guidelines) [<a href="#rid14">14,33,34</a>] (see  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Who should be treated with pharmacologic therapy?'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with out-of-office daytime blood pressure ≥135 mmHg systolic or ≥85 mmHg diastolic (or an average office blood pressure ≥140/90 mmHg if out-of-office readings are not available)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with an out-of-office daytime blood pressure ≥130 mmHg systolic or ≥80 mmHg diastolic (or an average of appropriately measured office blood pressures ≥130/80 mmHg if out-of-office readings are not available) who, in addition, have one or more of the following:</p><p class="bulletIndent2"><span class="glyph">•</span>Established clinical cardiovascular disease (eg, chronic coronary syndrome [stable ischemic heart disease], heart failure, carotid disease, previous stroke, or peripheral arterial disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Type 2 diabetes mellitus</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease</p><p class="bulletIndent2"><span class="glyph">•</span>Age 65 years or older</p><p class="bulletIndent2"><span class="glyph">•</span>An estimated 10-year risk of atherosclerotic cardiovascular disease of at least 10 percent (<a class="calc calc_professional" href="/d/html/107063.html" rel="external">calculator 1</a>)</p><p></p><p>These recommendations differ slightly from the 2020 ADA guidelines; specifically, the ADA suggests not starting antihypertensive drug therapy in a patient with type 2 diabetes and blood pressure &lt;140/&lt;90 mmHg if the predicted 10-year risk is &lt;10 percent.</p><p>Early treatment of hypertension is particularly important in patients with diabetes both to prevent cardiovascular disease and to minimize progression of kidney disease and diabetic retinopathy [<a href="#rid35">35</a>]. This is exemplified by the 21-year follow-up of the Steno diabetes study; specifically, appropriate management of systolic blood pressure, glycated hemoglobin (A1C), and low-density lipid (LDL) cholesterol resulted in a 20 percent absolute risk reduction at 13 years, a benefit that was persistent at 21 years [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H640628546"><span class="h2">Choice of antihypertensive drug therapy</span><span class="headingEndMark"> — </span>The choice of antihypertensive agents in patients with diabetes is based upon their ability to do the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent mortality</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent adverse cardiovascular events, such as myocardial infarction, stroke, and heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent the progression of kidney disease, if present</p><p></p><p>The choice is not based upon retinopathy endpoints, since comparative trials have not demonstrated superiority of one agent over another for retinopathy. (See  <a class="medical medical_review" href="/d/html/1773.html" rel="external">"Diabetic retinopathy: Prevention and treatment", section on 'Good blood pressure control'</a>.)</p><p class="headingAnchor" id="H680094009"><span class="h3">Overview of our approach</span><span class="headingEndMark"> — </span>Major guidelines including the 2017 ACC/AHA, European Society of Hypertension/European Society of Cardiology (ESH/ESC), ADA, and Canadian guidelines all conclude that the degree of blood pressure reduction is the major determinant of reduction in cardiovascular risk in both younger and older patients with hypertension (including patients with diabetes), <strong>not</strong> the choice of antihypertensive drug; this is also true in patients with diabetes [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>However, in patients with diabetic kidney disease, renin-angiotensin system inhibitors (angiotensin-converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]) may slow kidney disease progression more effectively than other antihypertensive drugs. In addition to kidney disease, placebo-controlled trials of ACE inhibitors and ARBs in high-risk patients have led some experts to conclude that these agents have a unique cardiovascular benefit in this setting [<a href="#rid39">39,40</a>]. However, the available data are more consistent with the conclusion that the achieved blood pressure, rather than the specific drug or drug class used, is the principal determinant of cardiovascular benefit. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>Based upon the effects of ACE inhibitors and ARBs on kidney disease progression, our overall approach in patients with diabetes who require antihypertensive therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with severely increased albuminuria, ≥300 mg/day (formerly called "macroalbuminuria" and sometimes called "very high albuminuria"), we treat with an ACE inhibitor or an ARB as part of the regimen to achieve the blood pressure goal. (See <a class="local">'Severely increased albuminuria (300 mg/day or higher)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also use these drugs in patients with moderately increased albuminuria (formerly called "microalbuminuria" and sometimes called "high albuminuria") who are hypertensive, even though the benefits of angiotensin inhibition on kidney disease progression in such patients are unproven. (See <a class="local">'Moderately increased albuminuria (30 to 299 mg/day)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients without increased albuminuria, initial monotherapy can consist of an ACE inhibitor, ARB, thiazide diuretic, or calcium channel blocker. However, because thiazide diuretics have the disadvantage of an adverse effect on glucose metabolism, many experts will choose an ACE inhibitor, ARB, or calcium antagonist as initial therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients whose blood pressure is &gt;20/10 mmHg above their goal, initial combination therapy (with a single pill, if available) should be prescribed. In addition, among patients with diabetes initiated on monotherapy, a second agent will often be required to attain goal blood pressure. In these settings (ie, when two antihypertensive drugs are needed), we generally treat with an ACE inhibitor or ARB plus a long-acting dihydropyridine calcium channel blocker. The combination of an ACE inhibitor or ARB with a diuretic is an acceptable alternative, and may be preferred in patients with edema; however, the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial suggested that combining an ACE inhibitor or ARB with a long-acting dihydropyridine calcium channel blocker was superior to the combination with a thiazide diuretic [<a href="#rid41">41</a>], including among patients with diabetes [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p></p><p class="bulletIndent1">When using two antihypertensive medications, a single-pill combination is usually preferred since it is associated with better medication adherence. (See  <a class="medical medical_review" href="/d/html/3845.html" rel="external">"Patient adherence and the treatment of hypertension", section on 'Methods to improve adherence'</a>.) </p><p></p><p>If an ACE inhibitor or ARB is indicated but cannot be used, alternative first-line agents include calcium channel blockers and diuretics. However, in patients with severely increased albuminuria, nondihydropyridine agents (eg, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) are generally preferred over dihydropyridine drugs (eg, <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>) since nondihydropyridine calcium channel blockers can reduce albuminuria [<a href="#rid43">43,44</a>].</p><p>Major side effects of ACE inhibitors and ARBs are reviewed separately. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p class="headingAnchor" id="H2431301808"><span class="h3">Severely increased albuminuria (300 mg/day or higher)</span><span class="headingEndMark"> — </span>In hypertensive patients with diabetes who have severely increased albuminuria, defined as a measured (eg, with a 24-hour urine collection) or estimated (eg, using a random urine albumin-to-creatinine ratio [ACR]) albumin excretion ≥300 mg/day, we recommend treatment with an ACE inhibitor or an ARB rather than other antihypertensive agents. Other drugs can be added, as needed, to attain the blood pressure goal.</p><p>This approach is based upon high-quality, randomized trials demonstrating that these agents slow the progression of kidney disease compared with alternative therapy [<a href="#rid45">45-48</a>]. In addition, indirect evidence from trials of nondiabetic individuals supports the conclusion that ACE inhibitors and ARBs reduce the risk of kidney failure among those with severely increased albuminuria [<a href="#rid49">49,50</a>]. However, ACE inhibitors and ARBs do not appear to decrease all-cause mortality or the incidence of major cardiovascular events compared with other antihypertensive drugs.</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 diabetes – The best data supporting angiotensin inhibition in patients with type 1 diabetes come from a trial of 409 adult participants who had urine protein excretion ≥500 mg/day and a serum creatinine ≤2.5 mg/dL (221 micromol/L) [<a href="#rid45">45,46</a>]. Patients were randomly assigned to <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a> (25 mg three-times daily) or placebo; other antihypertensive drugs, except for calcium channel blockers, were added if needed. Captopril reduced the rate of death or end-stage kidney disease (ESKD; 11 versus 21 percent) at three years, reduced the likelihood of doubling of serum creatinine (12 versus 21 percent), and slowed the annual loss of creatinine clearance (11 versus 17 percent per year). Smaller trials similarly concluded that ACE inhibitor slow the progression of kidney disease in patients with type 1 diabetes [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 2 diabetes – In type 2 diabetes, the best data comparing renin-angiotensin system inhibition with alternative therapy come from the <a class="drug drug_general" data-topicid="8640" href="/d/drug information/8640.html" rel="external">Irbesartan</a> Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">Losartan</a> (RENAAL) trial [<a href="#rid47">47,48</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In IDNT, 1715 participants aged 30 to 70 years with type 2 diabetes, hypertension, urine protein excretion ≥0.9 g/day, and mean serum creatinine of 1.7 mg/dL (150 micromol/L) were randomly assigned to <a class="drug drug_general" data-topicid="8640" href="/d/drug information/8640.html" rel="external">irbesartan</a> (75 to 300 mg once daily), <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a> (2.5 to 10 mg once daily), or placebo [<a href="#rid47">47</a>]. Target systolic blood pressure was ≤135 mmHg, or 10 mmHg lower than the value at screening (if systolic blood pressure at screening ≥145 mmHg), and target diastolic blood pressure was ≤85 mmHg. At 2.6 years, the likelihood of a doubling of serum creatinine was lower with irbesartan (17 percent) compared with amlodipine (25 percent) and placebo (24 percent); in addition, irbesartan nonsignificantly reduced the incidence of ESKD (14 versus 18 percent with amlodipine and placebo)  (<a class="graphic graphic_figure graphicRef80116" href="/d/graphic/80116.html" rel="external">figure 1</a>). Patients assigned to placebo had a higher blood pressure throughout the trial than those assigned irbesartan; however, the blood pressure in the irbesartan and amlodipine groups were similar, and therefore the benefits from irbesartan were independent of attained blood pressure [<a href="#rid53">53,54</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In RENAAL, 1513 adults with type 2 diabetes, albuminuria &gt;300 mg/day (median urinary ACR of approximately 1250 mg/g), and mean serum creatinine 1.9 mg/dL (168 micromol/L) were randomly assigned to <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> (50 titrating up to 100 mg once daily) or placebo; additional drugs were added as need to attain goal blood pressure [<a href="#rid48">48</a>]. At 3.4 years, the incidence of ESKD was lower with losartan (20 versus 26 percent), as was doubling of serum creatinine (22 versus 26 percent). Unlike IDNT, there was no active comparator, and the mean blood pressure throughout the study was lower among those assigned losartan.</p><p></p><p>ACE inhibitors and ARBs have similar effects on patient-important outcomes among patients with diabetes as well as among broader populations [<a href="#rid55">55-60</a>]. Thus, in general, either agent can be used when treating patients with diabetes and albuminuria.</p><p>Some studies suggest that ACE inhibitors are superior to ARBs in preventing mortality and cardiovascular events in patients with diabetes. As an example, a meta-analysis of 48 trials that compared ACE inhibitors or ARBs with either placebo or another antihypertensive drug found that ACE inhibitors significantly reduced mortality compared with placebo (9.3 versus 10.5 percent) but that ARBs did not reduce mortality compared with placebo (5 versus 5 percent) [<a href="#rid55">55</a>]. However, both ACE inhibitors and ARBs had similar, nonsignificant benefits on mortality when compared with another antihypertensive drug (10.2 versus 11.9 percent and 8.5 versus 10.5 percent, respectively). The lack of benefit when ARBs were compared with placebo may be due to the fact that one-half of these trials included lower-risk patients (ie, normotensive and/or those with normoalbuminuria). In addition, both drugs had significant benefits on heart failure; ACE inhibitors significantly reduced the risk of myocardial infarction, and ARBs significantly reduced the risk of stroke.</p><p>Other meta-analyses that included many of the same trials found that, in contrast to the study mentioned above, ARBs are equivalent to ACE inhibitors. One network meta-analysis, for example, used both direct and indirect comparisons to evaluate trials of antihypertensive therapy in patients with diabetes and found that ACE inhibitors and ARBs had identical effects on mortality and ESKD [<a href="#rid56">56</a>]. In addition, a meta-analysis that included patients with and without diabetes found that ACE inhibitors and ARBs reduced mortality and cardiovascular events to a similar degree [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H245537009"><span class="h3">Moderately increased albuminuria (30 to 299 mg/day)</span><span class="headingEndMark"> — </span>In hypertensive patients with diabetes who have moderately increased albuminuria, defined as a measured (eg, with a 24-hour urine collection) or estimated (eg, using a random urine ACR) albumin excretion 30 to 299 mg/day, we suggest treatment with an ACE inhibitor or ARB rather than other antihypertensive drugs. Additional agents are added, as needed, to attain the blood pressure goal.</p><p>The rationale for this approach comes from evidence that ACE inhibitors and ARBs, compared with other antihypertensive agents, can prevent the progression from moderately increased albuminuria to severely increased albuminuria in patients with diabetes [<a href="#rid61">61-63</a>]. In addition, these drugs may slow the rise in serum creatinine [<a href="#rid64">64</a>], and observational data suggest that a reduction in albuminuria is associated with a decreased incidence of ESKD [<a href="#rid65">65</a>].</p><p>However, there are <strong>no</strong> high-quality data that, in patients with moderately increased albuminuria, ACE inhibitors and ARBs are superior to other first-line agents in preventing kidney failure, all-cause mortality, or cardiovascular events.</p><p class="headingAnchor" id="H2909878369"><span class="h3">Normoalbuminuria (less than 30 mg/day)</span><span class="headingEndMark"> — </span>In patients without increased albuminuria (ie, measured or estimated albumin excretion &lt;30 mg/day), initial monotherapy can consist of an ACE inhibitor, ARB, thiazide diuretic, or calcium channel blocker. However, because thiazide diuretics have the disadvantage of an adverse, albeit minor, effect on glucose metabolism, many experts will choose an ACE inhibitor, ARB, or a calcium antagonist as initial therapy. This approach is generally similar to the selection of antihypertensive therapy in patients without diabetes. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>In patients with diabetes and normoalbuminuria, ACE inhibitors and ARBs do not provide superior protection against ESKD, all-cause mortality, and cardiovascular events, compared with other first-line drugs [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3700795642"><span class="h2">Avoid combination renin-angiotensin system inhibition</span><span class="headingEndMark"> — </span>A separate issue is whether an ARB should be given with an ACE inhibitor since combining these agents provides better blood pressure control compared with monotherapy and also reduces albuminuria to a greater degree [<a href="#rid66">66</a>]. However, based upon high-quality data in patients with diabetes as well as other individuals at high cardiovascular risk, we recommend <strong>against</strong> combination therapy with an ACE inhibitor and ARB or direct renin inhibitor [<a href="#rid67">67</a>].</p><p>In the subgroup analysis of the Ongoing <a class="drug drug_general" data-topicid="10275" href="/d/drug information/10275.html" rel="external">Telmisartan</a> Alone and in Combination with <a class="drug drug_general" data-topicid="9851" href="/d/drug information/9851.html" rel="external">Ramipril</a> Global Endpoint Trial (ONTARGET) trial cited above, ramipril, telmisartan, and combination therapy were compared in 6365 patients with diabetes [<a href="#rid59">59</a>]. There was no difference in the composite primary outcome of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure among these groups. However, in the entire cohort, which comprised 25,620 patients with vascular disease or diabetes, there was an increase in adverse side effects (including a possible increase in mortality) in patients who received both agents, compared with those who received ramipril alone [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"</a>.)</p><p>In addition, the combination of an ACE inhibitor with an ARB or with a direct renin inhibitor in two other large trials of patients with diabetic chronic kidney disease (<a class="drug drug_general" data-topicid="9282" href="/d/drug information/9282.html" rel="external">Aliskiren</a> Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints [ALTITUDE] and Veterans Affairs Nephropathy in Diabetes [VA NEPHRON-D]) was not superior to ACE inhibitor monotherapy and produced more side effects. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p>A subsequent multiple-treatment comparison (network) meta-analysis suggested that combination therapy with an ACE inhibitor and ARB was superior to placebo in preventing ESKD in patients with diabetes and hypertension [<a href="#rid68">68</a>]. However, monotherapy with either an ACE inhibitor or an ARB produced similar benefits compared with placebo, and combination therapy produced more adverse effects.</p><p class="headingAnchor" id="H3025737161"><span class="h1">INDICATIONS FOR ALTERNATIVE ANTIHYPERTENSIVE DRUGS</span><span class="headingEndMark"> — </span>The choice of initial antihypertensive therapy may vary from the approach described above if the patient has one of the following disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>A recent myocardial infarction (ie, in the previous three years) (see <a class="local">'Patients with a recent myocardial infarction'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure (see <a class="local">'Patients with heart failure'</a> below)</p><p></p><p class="headingAnchor" id="H107630297"><span class="h2">Patients with a recent myocardial infarction</span><span class="headingEndMark"> — </span>Beta blockers, while generally not recommended as initial monotherapy or as part of combination therapy in patients with hypertension, are indicated in patients who have had a myocardial infarction in the previous three years. Patients who have had a myocardial infarction are also frequently prescribed an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), regardless of whether they have albuminuria. (See  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy", section on 'Long-term therapy'</a> and  <a class="medical medical_review" href="/d/html/74.html" rel="external">"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use"</a>.)</p><p>Although there are concerns about masking of hypoglycemic symptoms and possible exacerbation of peripheral artery disease, beta blockers can effectively lower blood pressure in patients with diabetes. Among beta blockers, <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a>, a combined nonselective beta- and alpha-1 adrenergic antagonist that improves survival in patients with heart failure, may have certain advantages compared with other beta blockers in patients with diabetes [<a href="#rid69">69,70</a>]. However, <a class="drug drug_general" data-topicid="9158" href="/d/drug information/9158.html" rel="external">bisoprolol</a> and <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> extended release are reasonable alternatives.</p><p>This issue was best addressed in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial of 1235 patients with hypertension (&gt;130/80 mmHg) and type 2 diabetes; all patients were treated with an ACE inhibitor or ARB, while other antihypertensive drugs were discontinued [<a href="#rid69">69</a>]. The patients were then randomly assigned to <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a> (6.25 to 25 mg twice daily) or <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> (50 to 200 mg twice daily); <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> and a dihydropyridine calcium channel blocker were added as necessary to achieve a blood pressure below 130/80 mmHg.</p><p><a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">Carvedilol</a> was associated with the following significant benefits at five months; the blood pressure was similar in the two groups:</p><p class="bulletIndent1"><span class="glyph">●</span>No change in glycated hemoglobin (A1C) compared with a mean 0.15 percent increase with <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> and an increase in insulin sensitivity (9.1 percent) and compared with no change with metoprolol. In addition, fewer patients withdrew from the trial because of worsening glycemic control (0.6 versus 2.2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lower rate of progression to moderately increased albuminuria in patients in whom this was not present at baseline (6.6 versus 11.1 percent with <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>) and a 16 percent relative reduction in albumin excretion.</p><p></p><p>The modest worsening of glycemic control seen with <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> has also been noted in studies of other beta blockers [<a href="#rid71">71-73</a>].</p><p>In the United Kingdom Prospective Diabetes Study (UKPDS) study of patients with type 2 diabetes, <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> was as effective as <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a> in terms of both blood pressure lowering and protection against microvascular disease [<a href="#rid74">74</a>]. In the <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">Losartan</a> Intervention for Endpoint Reduction in Hypertension (LIFE) diabetic parallel study, however, losartan provided significantly more protection from adverse cardiovascular outcomes than atenolol [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H3064970266"><span class="h2">Patients with heart failure</span><span class="headingEndMark"> — </span>Heart failure is common in patients with diabetes. Those who have heart failure with reduced ejection fraction (HFrEF) are typically treated with renin-angiotensin system inhibitors (ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors [ARNIs]) whether or not they have albuminuria, since these drugs reduce mortality and morbidity in the setting of HFrEF. Patients who have heart failure with preserved ejection fraction (HFpEF) are often prescribed mineralocorticoid receptor antagonists because these agents may reduce morbidity in that population. Frequently, patients with HFpEF require multiple antihypertensive medications to control their blood pressure, and among those with diabetes, agent selection should follow the same approach as described above. (See <a class="local">'Overview of our approach'</a> above.)</p><p>Detailed discussions of pharmacologic therapy in patients with heart failure are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>HFrEF (see  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction"</a> and  <a class="medical medical_review" href="/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HFpEF (see  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a>)</p><p></p><p class="headingAnchor" id="H709615120"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Contributors to hypertension in patients with diabetes include kidney disease, extracellular fluid volume expansion, and increased arterial stiffness. Hypertension is common problem in patients with both type 1 and type 2 diabetes, but the time course in relation to the duration of diabetes is different. In type 1 diabetes, the prevalence of hypertension at the time of diagnosis is low, increasing subsequently over several decades. In type 2 diabetes, a substantial proportion of patients already have hypertension at the time of diabetes diagnosis. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, patients with diabetes are at higher cardiovascular risk compared with the general population, and therefore we target more intensive, rather than less intensive, blood pressure control. Our recommendations on goal blood pressure in hypertensive patients with diabetes mellitus are presented in detail elsewhere. Goal blood pressure also depends upon the method by which it is measured  (<a class="graphic graphic_table graphicRef117101" href="/d/graphic/117101.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension", section on 'Patients with diabetes mellitus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonpharmacologic interventions should be prescribed, as appropriate, to all patients with hypertension. These include salt restriction; weight reduction; increased consumption of fresh fruits, vegetables, and low-fat dairy products; increased exercise; and avoidance of smoking and excess alcohol ingestion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The decision to initiate drug therapy should be individualized and involve shared decision-making between patient and provider. In general, however, we initiate antihypertensive drug therapy in patients with diabetes who have an out-of-office daytime blood pressure ≥130 mmHg systolic or ≥80 mmHg diastolic (or an average of appropriately measured office blood pressures ≥130/80 mmHg if out-of-office readings are not available). (See <a class="local">'When to initiate antihypertensive drug therapy'</a> above and  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Who should be treated with pharmacologic therapy?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to the choice of antihypertensive therapy depends in part upon the degree of the patient's urine albumin excretion (see <a class="local">'Overview of our approach'</a> above and  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease", section on 'Severely increased albuminuria: Treat with angiotensin inhibition'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with severely increased albuminuria, ≥300 mg/day (formerly called "macroalbuminuria" and sometimes called "very high albuminuria"), we treat with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) as part of the regimen to achieve the blood pressure goal. (See <a class="local">'Severely increased albuminuria (300 mg/day or higher)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We also use these drugs in patients with moderately increased albuminuria (formerly called "microalbuminuria" and sometimes called "high albuminuria") who are hypertensive, even though the benefits of angiotensin inhibition on kidney disease progression in such patients are unproven. (See <a class="local">'Moderately increased albuminuria (30 to 299 mg/day)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients without increased albuminuria, initial monotherapy can consist of an ACE inhibitor, ARB, thiazide diuretic, or calcium channel blocker. However, because thiazide diuretics have the disadvantage of an adverse effect on glucose metabolism, albeit minor, many experts will choose an ACE inhibitor, ARB, or calcium antagonist as initial therapy. (See <a class="local">'Normoalbuminuria (less than 30 mg/day)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients whose blood pressure is &gt;20/10 mmHg above their goal, initial combination therapy (with a single pill, if available) should be prescribed. In addition, among patients with diabetes initiated on monotherapy, a second agent will often be required to attain goal blood pressure. In these settings (ie, when two antihypertensive drugs are needed), we generally treat with an ACE inhibitor or ARB plus a long-acting dihydropyridine calcium channel blocker. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an ACE inhibitor or ARB is indicated but cannot be used, alternative first-line agents include calcium channel blockers and diuretics. However, in patients with severely increased albuminuria, nondihydropyridine agents (eg, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) are generally preferred over dihydropyridine drugs (eg, <a class="drug drug_general" data-topicid="8627" href="/d/drug information/8627.html" rel="external">amlodipine</a>, <a class="drug drug_general" data-topicid="8438" href="/d/drug information/8438.html" rel="external">felodipine</a>), since nondihydropyridine calcium channel blockers can reduce albuminuria. (See <a class="local">'Overview of our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The choice of initial antihypertensive therapy may vary from the approach described above if the patient has one of the following disorders: a recent myocardial infarction (ie, in the previous three years), in which case a beta blocker is appropriate, or heart failure, in which case various antihypertensive agents may be appropriate regardless of the degree of albuminuria. (See <a class="local">'Indications for alternative antihypertensive drugs'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension 2021; 78:1197.</a></li><li><a class="nounderline abstract_t">Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403.</a></li><li><a class="nounderline abstract_t">Nosadini R, Sambataro M, Thomaseth K, et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int 1993; 44:139.</a></li><li><a class="nounderline abstract_t">Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106:2085.</a></li><li><a class="nounderline abstract_t">Viazzi F, Bonino B, Mirijello A, et al. Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. J Hypertens 2019; 37:805.</a></li><li><a class="nounderline abstract_t">van den Boom L, Buchal G, Kaiser M, Kostev K. Multimorbidity Among Adult Outpatients With Type 1 Diabetes in Germany. J Diabetes Sci Technol 2022; 16:152.</a></li><li><a class="nounderline abstract_t">Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3:19.</a></li><li><a class="nounderline abstract_t">Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296:156.</a></li><li><a class="nounderline abstract_t">Koebnick C, Imperatore G, Jensen ET, et al. Progression to hypertension in youth and young adults with type 1 or type 2 diabetes: The SEARCH for Diabetes in Youth Study. J Clin Hypertens (Greenwich) 2020; 22:888.</a></li><li><a class="nounderline abstract_t">Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991; 14 Suppl 4:13.</a></li><li><a class="nounderline abstract_t">Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309.</a></li><li><a class="nounderline abstract_t">Raghavan S, Ho YL, Kini V, et al. Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes. Diabetes Care 2019; 42:1995.</a></li><li><a class="nounderline abstract_t">Kabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr 2006; 1:95.</a></li><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S158.</a></li><li><a class="nounderline abstract_t">Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313:603.</a></li><li><a class="nounderline abstract_t">Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387:435.</a></li><li><a class="nounderline abstract_t">Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387:957.</a></li><li><a class="nounderline abstract_t">Adamsson Eryd S, Gudbjörnsdottir S, Manhem K, et al. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. BMJ 2016; 354:i4070.</a></li><li><a class="nounderline abstract_t">ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575.</a></li><li><a class="nounderline abstract_t">Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114.</a></li><li><a class="nounderline abstract_t">James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507.</a></li><li><a class="nounderline abstract_t">Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. (8) Cardiovascular disease and risk management. Diabetes Care 2015; 38 Suppl:S49.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42:S103.</a></li><li><a class="nounderline abstract_t">Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703.</a></li><li><a class="nounderline abstract_t">Executive summary: Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138:593.</a></li><li><a class="nounderline abstract_t">Snow V, Weiss KB, Mottur-Pilson C, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138:587.</a></li><li><a class="nounderline abstract_t">Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755.</a></li><li><a class="nounderline abstract_t">Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829.</a></li><li><a class="nounderline abstract_t">Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43:S111.</a></li><li><a class="nounderline abstract_t">de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care 2017; 40:1273.</a></li><li><a class="nounderline abstract_t">Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353:617.</a></li><li><a class="nounderline abstract_t">Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59:2298.</a></li><li><a class="nounderline abstract_t">Oellgaard J, Gæde P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 2018; 61:1724.</a></li><li><a class="nounderline abstract_t">Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 2016; 352:i438.</a></li><li><a class="nounderline abstract_t">Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253.</a></li><li><a class="nounderline abstract_t">Daly CA, Fox KM, Remme WJ, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26:1369.</a></li><li><a class="nounderline abstract_t">Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.</a></li><li><a class="nounderline abstract_t">Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56:77.</a></li><li><a class="nounderline abstract_t">Birkenhäger WH, Staessen JA. Treatment of diabetic patients with hypertension. Curr Hypertens Rep 1999; 1:225.</a></li><li><a class="nounderline abstract_t">Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65:1991.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456.</a></li><li><a class="nounderline abstract_t">Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int 1994; 46:1688.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851.</a></li><li><a class="nounderline abstract_t">Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861.</a></li><li><a class="nounderline abstract_t">Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73.</a></li><li><a class="nounderline abstract_t">Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18:1959.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129.</a></li><li><a class="nounderline abstract_t">Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60:228.</a></li><li><a class="nounderline abstract_t">Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170.</a></li><li><a class="nounderline abstract_t">Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16:3027.</a></li><li><a class="nounderline abstract_t">Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014; 174:773.</a></li><li><a class="nounderline abstract_t">Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013; 347:f6008.</a></li><li><a class="nounderline abstract_t">Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013; 61:131.</a></li><li><a class="nounderline abstract_t">Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952.</a></li><li><a class="nounderline abstract_t">ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.</a></li><li><a class="nounderline abstract_t">Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.</a></li><li><a class="nounderline abstract_t">Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870.</a></li><li><a class="nounderline abstract_t">Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30:1577.</a></li><li><a class="nounderline abstract_t">Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98:S1.</a></li><li><a class="nounderline abstract_t">Heerspink HJ, Kröpelin TF, Hoekman J, et al. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol 2015; 26:2055.</a></li><li><a class="nounderline abstract_t">Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440.</a></li><li><a class="nounderline abstract_t">Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4:90.</a></li><li><a class="nounderline abstract_t">Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015; 385:2047.</a></li><li><a class="nounderline abstract_t">Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.</a></li><li><a class="nounderline abstract_t">Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955.</a></li><li><a class="nounderline abstract_t">Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706.</a></li><li><a class="nounderline abstract_t">Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:905.</a></li><li><a class="nounderline abstract_t">Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM 2006; 99:431.</a></li><li><a class="nounderline abstract_t">Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713.</a></li><li><a class="nounderline abstract_t">Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004.</a></li></ol></div><div id="topicVersionRevision">Topic 3829 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34601960" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568757" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diabetes mellitus and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355455" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12379578" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30817462" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33095037" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Multimorbidity Among Adult Outpatients With Type 1 Diabetes in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018975" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chapter 1: Definition and classification of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122980" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32297456" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Progression to hypertension in youth and young adults with type 1 or type 2 diabetes: The SEARCH for Diabetes in Youth Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1748053" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8387089" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515207" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679829" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36507632" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25668264" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26559744" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26724178" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27492939" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20228401" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of intensive blood-pressure control in type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192512" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24352797" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817082" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537708" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : (8) Cardiovascular disease and risk management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559236" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732337" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042774" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Executive summary: Standards of medical care in diabetes--2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12667032" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12667031" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9635947" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765963" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983291" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862753" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28830958" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diabetes and Hypertension: A Position Statement by the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030326" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27531506" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29850922" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868137" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675071" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860521" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19052124" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620720" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cardiovascular events during differing hypertension therapies in patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10981070" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of diabetic patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149313" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Differential effects of calcium antagonist subclasses on markers of nephropathy progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413456" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7700028" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565517" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565518" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453706" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17475813" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416309" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422755" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930097" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120823" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687000" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24157497" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219304" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516696" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378520" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Telmisartan, ramipril, or both in patients at high risk for vascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18707986" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565519" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389334" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8452322" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32998798" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25421558" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110735" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400053" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Combination therapy in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26009228" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536109" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182472" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490538" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738048" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16766516" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732338" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11937179" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
